ArticleBriefings in bioinformatics2025
Non-apoptotic regulated cell death based prognostic risk model for colorectal cancer using machine learning guided two-step framework.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pyroptosis as a double-edged sword in colorectal cancer: Molecular mechanisms and therapeutic opportunities.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Colorectal cancer (CRC) prognosis is severely limited by tumor heterogeneity. To address this, we leveraged the emerging role of non-apoptotic regulated cell death (NARCD) pathways to develop a two-step machine learning (ML) framework to develop a prognostic risk model. We used two largest and independent CRC patient cohorts (TCGA and E-MTAB-12862). Our novel pipeline consists of two steps, first, a library of 46 combination ML survival models was applied to each of the 13 NARCD pathways to establish robust, pathway-specific prognostic models. Second, logistic regression was used to integrate these models, revealing that the synergistic combination of ferroptosis, NETosis, pyroptosis, and autosis yielded the highest predictive power. The resulting 43-gene prognostic risk model, the combined-regulated cell death index (c-RCDI), robustly stratified patients and proved to be a powerful independent prognostic factor (HR = 55.1, P < 0.001), with high predictive accuracy (5-year AUROC = 0.88). Notably, this prognostic power was exclusive to CRC. Biologically, the high-risk class showed enriched angiogenesis and EMT pathways, an immunosuppressive microenvironment, reduced immunotherapy response, and predicted increased sensitivity to CDK, MEK, and metabolic inhibitors, while the low-risk class showed increased sensitivity to the drug "Obatoclax Mesylate_1068". c-RCDI developed in this study using a novel two-step ML framework based on NARCD pathways showed robust predictive ability for CRC patients, with a potential for improving diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.